Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.

ChemMedChem - 1 Nov 2008

Jones Lyn H, Allan Gill, Corbau Romuald, Hay Duncan, Middleton Donald S, Mowbray Charles E, Newman Sandra D, Perros Manos, Randall Amy, Vuong Hannah, Webster Rob, Westby Mike, Williams David

Abstract excerpt

A major problem associated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV is their vulnerability to mutations in the allosteric binding site of reverse transcriptase that can result in the development of a resistant virus. Herein we present the optimization of a series of 5-aryloxy imidazoles, which possess a balanced pharmacological profile against both wild-type enzyme...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acquired Immunodeficiency Syndrome
Share to Allosteric Site

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemistry, Pharmaceutical

Share to Drug Design

Share to HIV Reverse Transcriptase

Share to Imidazoles

Share to Inhibitory Concentration 50

Share to Models, Chemical

Source

Identifiers

PMID: 18855969
DOI: 10.1002/cmdc.200800183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors.PMID 18855969Read ↗

Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse TranscriptaseSemantic proximity Read ↗

Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase.Semantic proximity Read ↗

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.Semantic proximity Read ↗

Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1Semantic proximity Read ↗

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.Semantic proximity Read ↗

Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs).Semantic proximity Read ↗

In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Semantic proximity Read ↗

Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.Semantic proximity Read ↗

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.Semantic proximity Read ↗

Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motifSemantic proximity Read ↗

Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.Semantic proximity Read ↗

Synthesis and biological evaluation of aryl-phospho-indole as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.